Aegerion Pharmaceuticals, Inc. 4
4 · Aegerion Pharmaceuticals, Inc. · Filed Jan 31, 2012
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2012-01-30$17.06/sh−2,670$45,563→ 2,551,716 total(indirect: See Footnote) - Sale
Common Stock
2012-01-27$17.17/sh−49,448$848,800→ 2,554,386 total(indirect: See Footnote) - Sale
Common Stock
2012-01-31$17.10/sh−22,054$377,156→ 2,529,662 total(indirect: See Footnote)
Footnotes (1)
- [F1]These securities are indirectly beneficially owned in the following capacity: as General Partner of AHLS III GP Limited partnership which in turn is the General Partner of Advent Healthcare and Life Sciences III Limited Partnership and Advent Healthcare and Life Sciences III-A Limited Partnership.